These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial. Mehilli J; Ndrepepa G; Kastrati A; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Kufner S; Dirschinger J; Berger PB; Schömig A Am Heart J; 2007 Jul; 154(1):158.e1-7. PubMed ID: 17584569 [TBL] [Abstract][Full Text] [Related]
7. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis. Moustapha A; Assali AR; Sdringola S; Yusuf SW; Vaughn WK; Fish RD; Schroth GW; Krajcer Z; Rosales OR; Smalling RW; Anderson HV Catheter Cardiovasc Interv; 2002 Jun; 56(2):184-7. PubMed ID: 12112910 [TBL] [Abstract][Full Text] [Related]
8. Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel. Schühlen H; Kastrati A; Mehilli J; Hausleiter J; Dirschinger J; Dotzer F; Bollwein H; Schömig A Am Heart J; 2006 Jun; 151(6):1248-54. PubMed ID: 16781230 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748 [TBL] [Abstract][Full Text] [Related]
10. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334 [TBL] [Abstract][Full Text] [Related]
11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670 [TBL] [Abstract][Full Text] [Related]
12. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial. van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325 [TBL] [Abstract][Full Text] [Related]
13. Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention. Sim DS; Jeong MH; Kim W; Rhew JY; Yum JH; Kim JH; Cho JG; Ahn YK; Park JC; Ahn BH; Kim SH; Kang JC Korean J Intern Med; 2003 Sep; 18(3):129-37. PubMed ID: 14619381 [TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A; Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766 [TBL] [Abstract][Full Text] [Related]
15. Abciximab improves 6-month clinical outcome after rescue coronary angioplasty. Petronio AS; Musumeci G; Limbruno U; De Carlo M; Baglini R; Paterni G; Grazia Delle Donne M; Caravelli P; Nardi C; Mariani M Am Heart J; 2002 Feb; 143(2):334-41. PubMed ID: 11835040 [TBL] [Abstract][Full Text] [Related]
16. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study. De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571 [TBL] [Abstract][Full Text] [Related]
17. Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). Islam MA; Blankenship JC; Balog C; Iliadis EA; Lincoff AM; Tcheng JE; Califf RM; Topol EJ; Am J Cardiol; 2002 Nov; 90(9):916-21. PubMed ID: 12398954 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center. Zahn R; Fraiture B; Siegler KE; Schneider S; Gitt AK; Seidl K; Gandjour A; Wendland G; Vogt S; Lauterbach KW; Senges J Z Kardiol; 2003 Jun; 92(6):438-44. PubMed ID: 12819992 [TBL] [Abstract][Full Text] [Related]
20. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A; N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]